Table 1. Summary of joint Bliss and Loewe synergy and antagonism analyses of drug pairs when exposed to 6 different colorectal cell lines, one for each column.
| Combination | HCT116 | HCT116KRAS/- | DLD-1 | DLD-1KRAS/- | RKO | RKOBRAF/-/- |
|---|---|---|---|---|---|---|
| Erlotinib & Sorafenib | -- | -- | -- | -- | -- | -- |
| Erlotinib & Sunitinib | O | O | X | X | -- | -- |
| 5FU & Irinotecan | -- | -- | -- | -- | -- | -- |
| 5FU & Oxaliplatin | -- | O | O | -- | O | -- |
| Sorafenib & 5FU | -- | -- | -- | -- | -- | -- |
| Sorafenib & Irinotecan | -- | -- | -- | -- | -- | -- |
| Sorafenib & Oxaliplatin | -- | -- | -- | -- | -- | -- |
| Sunitinib & Irinotecan | -- | -- | -- | -- | -- | -- |
| Sunitinib & Oxaliplatin | -- | -- | -- | O | -- | O |
| Sunitinib & 5FU | O | -- | -- | -- | NA | O |
| Erlotinib & 5FU | -- | X | -- | -- | -- | -- |
| Erlotinib & Irinotecan | X | X | NA | X | -- | -- |
| Erlotinib & Oxaliplatin | -- | -- | O | NA | O | O |
| VLX600 & Irinotecan | -- | -- | X | -- | NA | -- |
| VLX600 & Oxaliplatin | X | -- | -- | -- | -- | -- |
Each element in the table, which corresponds to one particular drug combination and cell line, is marked by “X” in case there exists a joint Bliss and Loewe synergy (occurs when the bootstrap interval of Imax under the Bliss or Loewe null model does not include observed Imax), and by “O” if there exists a joint Bliss and Loewe antagonism (occurs when bootstrap interval of Imin does not include observed Imin). Symbol “--” represents combinations where no global joint Bliss and Loewe synergy or antagonism exists. For the cases where there is no data collected or where Loewe analysis cannot be performed (due to an almost constant concentration-response relationship according to the experimental data collected) the element is marked “NA”. Detailed summary results for each Bliss and Loewe analysis are shown in Supplementary Table 1 and Supplementary Table 2.